GET A QUOTE

Folate Receptor Alpha: Gateway to Precision Medicine in Cancer and Neural Development

Molecular Architecture and Regulation FOLR1’s Sophisticated Transport Machinery

Folate Receptor Alpha (known as FOLR1) a protein linked to glycosylphosphatidylinositol (GPI) is vital, for maintaining the balance of folates within cells. This protein has 257 acids, contains multiple sites where sugar molecules can attach (glycosylation). It is produced by the FOLRL gene on chromosome 11 at position q13. Its design includes a pocket that binds to folic acid and other folates strongly (with a binding strength of around kd ~ 1 nM). The expression of FOLRL1 is influenced by factors like levels of folates in the body and certain hormones like steroids and transcription factors such, as HIF-1alpha. The transportation of the protein, within cells includes processes such as endocytosis without clathrin and pathways for recycling. It is essential for the folding and function of proteins that post translational modifications like glycosylation are carefully considered. Understanding how FOLR-1 binds to folate and where it is distributed within cells has played a role, in developing treatment approaches.

Physiological Functions Beyond Simple Folate Transport

The main function of FOLR1 goes beyond transporting folate; it plays a role, in the uptake of essential cofactors for one-carbon metabolism and nucleotide synthesis in normal body processes like cell division and embryonic growths. Additionally influences cell growth through signal pathways. Has been recently discovered to regulate responses while contributing to the maintenance of cellular polarity, in epithelial tissues. The role of the receptor, in development is very important because it helps provide folate to the developing nervous system – a key factor, in preventing neural tube defects and ensuring healthy brain development.

FOLR1 in Development and Disease from Neural Tube Formation to Cancer

The significant importance of FOLR1, in the development and progression of diseases is widely. Extensively studied in the community. Throughout the stages of development and growth within the womb (embryogenesis) it is crucial for FOLR1 to be expressed adequately to ensure the closure of the tube and proper formation of the brain. Any alterations or malfunction in FOLR-1 can result in abnormalities during development such as folate deficiency and defects in the neural tube. In cases of cancer onset and progression within individual’s bodies (oncogenesis) there is an occurrence where FOLR1 is found to be expressed across various types of malignant tumors; most notably ovarian cancers along with lung and breast carcinomas. This amplified expression pattern has been associated with outcomes, for patients diagnosed with cancer as it tends to coincide with a prognosis and an increased likelihood of metastasis occurring.

Targeting FOLR1 in Cancer the Rise of Antibody-Drug Conjugates

Using FOLR1 for purposes has become an approach, in treating cancer effectively. Antibody drug conjugates (ADCs) designed for FOLR-1 present an option by combining FOLR1 antibodies precision with powerful cytotoxic components. Multiple ADC treatments are currently undergoing trials. Exhibiting impressive outcomes against FOLR-1 positive cancers. These methods utilize FOLR1s ability to internalize substances to transport agents directly to cells while reducing overall toxicity, in the body. Other, than ADCs (Antibody drug conjugates) there are treatment methods like medications linked with folate (vitamin B9) molecule inhibitors that interfere with specific biological processes in cells and immunotherapeutic techniques aimed at boosting the body’s immune system response against diseases or cancer cells. Creating tests that can pinpoint which patients would derive the benefit from therapies targeting FOLR1 has emerged as an element, in advancing this treatment strategy.

Future Horizons Emerging Applications in Diagnostics and Therapeutics

State of the art technologies in imaging and diagnostics are leveraging FOLR1 as a biomarker for the detection and surveillance of diseases. Cutting edge therapeutic methods are under development that encompass bispecific antibodies and innovative drug delivery systems aimed at targeting FOLR1 alongside CAR-T cell therapies. Combining FOLR-1 targeted treatments, with therapy options, like immunotherapy and traditional chemotherapy shows potential in improving treatment results.

Suitable ELISA Kits

Online Enquiry Form

"*" indicates required fields

Please check mark information required:

TESTIMONIALS arrow icon

Your secretory IgA ELISA gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA assay performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA assay's from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford